CGEN
Price
$1.76
Change
+$0.02 (+1.15%)
Updated
Jul 3 closing price
Capitalization
165.65M
24 days until earnings call
XBIO
Price
$3.70
Change
-$0.24 (-6.09%)
Updated
Jul 3 closing price
Capitalization
5.71M
Interact to see
Advertisement

CGEN vs XBIO

Header iconCGEN vs XBIO Comparison
Open Charts CGEN vs XBIOBanner chart's image
Compugen
Price$1.76
Change+$0.02 (+1.15%)
Volume$94.6K
Capitalization165.65M
Xenetic Biosciences
Price$3.70
Change-$0.24 (-6.09%)
Volume$40.95K
Capitalization5.71M
CGEN vs XBIO Comparison Chart in %
Loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGEN vs. XBIO commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a Hold and XBIO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (CGEN: $1.76 vs. XBIO: $3.70)
Brand notoriety: CGEN and XBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 42% vs. XBIO: 49%
Market capitalization -- CGEN: $165.65M vs. XBIO: $5.71M
CGEN [@Biotechnology] is valued at $165.65M. XBIO’s [@Biotechnology] market capitalization is $5.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 1 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).

  • CGEN’s FA Score: 1 green, 4 red.
  • XBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, both CGEN and XBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 4 TA indicator(s) are bullish while XBIO’s TA Score has 5 bullish TA indicator(s).

  • CGEN’s TA Score: 4 bullish, 4 bearish.
  • XBIO’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, XBIO is a better buy in the short-term than CGEN.

Price Growth

CGEN (@Biotechnology) experienced а +7.98% price change this week, while XBIO (@Biotechnology) price change was -7.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

CGEN is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGEN($166M) has a higher market cap than XBIO($5.71M). CGEN YTD gains are higher at: 15.033 vs. XBIO (-7.268). XBIO has higher annual earnings (EBITDA): -3.88M vs. CGEN (-14.79M). CGEN has more cash in the bank: 104M vs. XBIO (5.16M). XBIO has less debt than CGEN: XBIO (153K) vs CGEN (2.77M). CGEN has higher revenues than XBIO: CGEN (27.6M) vs XBIO (2.58M).
CGENXBIOCGEN / XBIO
Capitalization166M5.71M2,909%
EBITDA-14.79M-3.88M381%
Gain YTD15.033-7.268-207%
P/E Ratio60.33N/A-
Revenue27.6M2.58M1,069%
Total Cash104M5.16M2,014%
Total Debt2.77M153K1,811%
FUNDAMENTALS RATINGS
CGEN vs XBIO: Fundamental Ratings
CGEN
XBIO
OUTLOOK RATING
1..100
5049
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
4943
P/E GROWTH RATING
1..100
31100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XBIO's Valuation (20) in the Biotechnology industry is somewhat better than the same rating for CGEN (76). This means that XBIO’s stock grew somewhat faster than CGEN’s over the last 12 months.

XBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CGEN (100). This means that XBIO’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's SMR Rating (95) in the Biotechnology industry is in the same range as XBIO (97). This means that CGEN’s stock grew similarly to XBIO’s over the last 12 months.

XBIO's Price Growth Rating (43) in the Biotechnology industry is in the same range as CGEN (49). This means that XBIO’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's P/E Growth Rating (31) in the Biotechnology industry is significantly better than the same rating for XBIO (100). This means that CGEN’s stock grew significantly faster than XBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENXBIO
RSI
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
85%
Bullish Trend 5 days ago
90%
Momentum
ODDS (%)
Bullish Trend 5 days ago
86%
Bullish Trend 5 days ago
84%
MACD
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 5 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
81%
Bearish Trend 5 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 5 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 12 days ago
84%
Declines
ODDS (%)
Bearish Trend 12 days ago
89%
N/A
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
90%
Aroon
ODDS (%)
Bullish Trend 5 days ago
76%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ASM3.500.13
+3.86%
Avino Silver & Gold Mines Ltd
TOST43.581.04
+2.44%
Toast
PSBD14.030.18
+1.30%
Palmer Square Capital BDC
CABO137.361.15
+0.84%
Cable One
ESGL3.10-0.07
-2.06%
ESGL Holdings Limited

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with BDTX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then BDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
+1.15%
BDTX - CGEN
46%
Loosely correlated
-0.77%
ROIV - CGEN
41%
Loosely correlated
+0.18%
ARWR - CGEN
40%
Loosely correlated
-0.65%
RLAY - CGEN
40%
Loosely correlated
+0.83%
BBIO - CGEN
40%
Loosely correlated
+2.71%
More

XBIO and

Correlation & Price change

A.I.dvisor tells us that XBIO and ELEV have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XBIO and ELEV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBIO
1D Price
Change %
XBIO100%
-6.09%
ELEV - XBIO
28%
Poorly correlated
+2.46%
VERA - XBIO
27%
Poorly correlated
N/A
ALT - XBIO
26%
Poorly correlated
-2.86%
NKTR - XBIO
25%
Poorly correlated
-3.02%
CGEN - XBIO
24%
Poorly correlated
+1.15%
More